Birtamimab  (Synonyms: NEOD001)

Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Amyloid Beta/Aβ

Birtamimab can neutralize circulating soluble amyloid and deposited insoluble amyloid, thus promoting the phagocytic clearance of amyloid deposits^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

351  [NCBI]

P05067

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.44 kDa

1608108-91-3

Liquid

Colorless to light yellow

[Birtamimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized SAA1 Protein, Human (His, HY-P70510) can bind Birtamimab. The EC₅₀ for this effect is 677.9 ng/mL.
• 
  Flow cytometric analysis of 1.5×10⁶ HUVEC cells with Birtamimab (HY-P99481, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control).

• [1]. AGertz M, et, al. Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design. Journal home page for Blood. Volume 138, Supplement 1, 23 November 2021, Page 2754.